Business NewsPR NewsWire • Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients

Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients

Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients

HORSHOLM, Denmark, June 23, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that two-year results of the pivotal Phase 3 clinical trial, Study 3002, of Envarsus® XR (tacrolimus extended-release tablets) in de novo kidney transplant patients continued to...

View More : http://www.prnewswire.com/news-releases/veloxis-announces-positive-two-year-results-from-pivotal-phase-3-study-of-envars...
Releted News by prnewswire
Electronic Recycling (Copper, Steel, Plastic resins) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019
Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients
Flexible Packaging (Plastic, Paper, Aluminum Foil and Others) Market for Food & Beverages, Retail Non-Food, Pharmaceutical and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019